Dipti Talaulikar

List of Publications by Year
in descending order

58	1,210	430874 18	395702 33
papers	citations	h-index	g-index

59	59	59	1990
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive genomic testing is required to assess for markers of poor prognosis in multiple myeloma. Pathology, 2022, 54, 111-113.	0.6	2
2	Extramedullary hematopoiesis: mesenchymal stromal cells from spleen provide an in vitro niche for myelopoiesis. In Vitro Cellular and Developmental Biology - Animal, 2022, 58, 429-439.	1.5	1
3	Bleeding Propensity in WaldenstrÃ¶m Macroglobulinemia: Potential Causes and Evaluation. Thrombosis and Haemostasis, 2022, 122, 1843-1857.	3.4	3
4	Retrospective singleâ€centre analysis of diagnostic approach to adultâ€onset haemophagocytic lymphohistiocytosis. Internal Medicine Journal, 2021, 51, 939-947.	0.8	1
5	Role of cell-free DNA in haematological malignancies. Pathology, 2021, 53, 416-426.	0.6	11
6	Malignant haematology 2021: impact of recent advances on the diagnostic laboratory. Pathology, 2021, 53, 297-299.	0.6	0
7	Genomic characterisation of diffuse large B-cell lymphoma. Pathology, 2021, 53, 367-376.	0.6	9
8	Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 2021, 5, 2644-2649.	5.2	7
9	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical Cancer Research, 2021, 27, 6323-6332.	7.0	42
10	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 2021, 51, 1707-1712.	0.8	1
11	Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance. HemaSphere, 2021, 5, e648.	2.7	3
12	The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma. Blood, 2021, 138, 3513-3513.	1.4	0
13	A practical guide to laboratory investigations at diagnosis and follow up in WaldenstrÃ¶m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 2020, 52, 167-178.	0.6	23
14	Consensus Statement on the Management of WaldenstrÃ¶m Macroglobulinemia Patients During the COVIDâ€19ÂPandemic. HemaSphere, 2020, 4, e433.	2.7	11
15	Consensus treatment recommendations from the tenth International Workshop for WaldenstrÃ¶m Macroglobulinaemia. Lancet Haematology,the, 2020, 7, e827-e837.	4.6	96
16	Genomic profiling of CD20 negative diffuse large B cell lymphoma identifies targetable mutations: A case report. EJHaem, 2020, 1, 593-595.	1.0	1
17	Zanubrutinib for the treatment of MYD88 wild-type WaldenstrÃ¶m macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Advances, 2020, 4, 6009-6018.	5.2	57
18	High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(â¯/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma. BMC Cancer, 2020, 20, 1061.	2.6	2

#	Article	IF	Citations
19	LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 1367-1377.	5.2	66
20	Bendamustine Plus Rituximab for the Treatment of WaldenstrÃ¶m Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing. Blood, 2020, 136, 10-11.	1.4	4
21	Correlation of Hemophagocytosis with Clinical Criteria of Hemophagocytic Lymphohistiocytosis and Recommendations for Screening Bone Marrow Samples in Adult Patients. Blood, 2020, 136, 37-38.	1.4	0
22	Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. Blood, 2020, 136, 36-38.	1.4	0
23	Somatic Mutations Associated with IgVH4-34 FR1 Region Unmutated QW and Avy Motifs in DLBCL Patients. Blood, 2020, 136, 20-21.	1.4	0
24	The Genetic Landscape in Elderly DLBCL Aged > 75 Years in the Australasian Leukaemia & Lymphoma Group NHL29 Iric Trial Identifies New Targetable Mutations. Blood, 2020, 136, 18-20.	1.4	1
25	Non-parametric Heat Map Representation of Flow Cytometry Data: Identifying Cellular Changes Associated With Genetic Immunodeficiency Disorders. Frontiers in Immunology, 2019, 10, 2134.	4.8	8
26	The tumour microenvironment is immunoâ€tolerogenic and a principal determinant of patient outcome in EBVâ€positive diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2019, 103, 200-207.	2.2	42
27	Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large Bâ€cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. British Journal of Haematology, 2019, 187, 174-184.	2.5	23
28	Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 2019, 3, 2804-2811.	5.2	15
29	Genetic analysis of Diffuse Large Bâ€cell Lymphoma occurring in cases with antecedent WaldenstrÃ¶m Macroglobulinaemia reveals different patterns of clonal evolution. British Journal of Haematology, 2019, 185, 767-770.	2.5	13
30	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood, 2019, 133, 299-305.	1.4	69
31	The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. Blood, 2019, 134, 3986-3986.	1.4	2
32	Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood, 2018, 131, 1809-1819.	1.4	231
33	Acquired Î±-thalassemia associated with myelodysplastic syndromes. Blood, 2018, 132, 2209-2209.	1.4	1
34	A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. Oncotarget, 2018, 9, 23620-23627.	1.8	19
35	Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma. Oncotarget, 2018, 9, 34644-34657.	1.8	14
36	Treatment of patients with WaldenstrÃ¶m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 2017, 47, 35-49.	0.8	10

#	Article	IF	Citations
37	Role of plasma cells in WaldenstrÃ¶m macroglobulinaemia. Pathology, 2017, 49, 337-345.	0.6	14
38	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Internal Medicine Journal, 2017, 47, 938-951.	0.8	19
39	The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma. Clinical Cancer Research, 2017, 23, 1820-1828.	7.0	65
40	Delineation of a novel dendritic-like subset in human spleen. Cellular and Molecular Immunology, 2016, 13, 443-450.	10.5	9
41	DeepSNVMiner: a sequence analysis tool to detect emergent, rare mutations in subsets of cell populations. PeerJ, 2016, 4, e2074.	2.0	23
42	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology,the, 2015, 2, e445-e455.	4.6	74
43	Net antitumoral immunity and the predictive power of conventional prognosticators in diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2014, 32, 8542-8542.	1.6	0
44	Genetics of Disease Progression in Diffuse Large B-Cell Lymphoma: Clonal Selection and Acquisition of Newly Acquired Somatic Mutations at Relapse. Blood, 2014, 124, 3038-3038.	1.4	0
45	Utilisation of s<scp>FLC</scp> assays â€“ how well do we comply with guidelines?. International Journal of Laboratory Hematology, 2013, 35, 200-210.	1.3	3
46	Novel therapeutic option for orbital atypical lymphoid hyperplasia. Clinical and Experimental Ophthalmology, 2010, 38, 892-894.	2.6	7
47	Staging bone marrow in diffuse large B-cell lymphoma: the role of ancillary investigations. Pathology, 2009, 41, 214-222.	0.6	22
48	Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). Journal of Hematology and Oncology, 2009, 2, 49.	17.0	18
49	Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) â€“ a new perspective. Histopathology, 2008, 52, 340-347.	2.9	14
50	Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leukemia and Lymphoma, 2008, 49, 959-964.	1.3	39
51	Role of Immunohistochemistry in Staging Diffuse Large B-cell Lymphoma (DLBCL). Journal of Histochemistry and Cytochemistry, 2008, 56, 893-900.	2.5	15
52	DNA amplification from formalin-fixed decalcified paraffin-embedded bone marrow trephine specimens: does the duration of storage matter?. Pathology, 2008, 40, 702-706.	0.6	18
53	Bench work and clinical relevance: a new strategy in pathology education. Pathology, 2008, 40, 707-710.	0.6	3
54	Clinical Implications of Immunophenotyping in Staging Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 5279-5279.	1.4	1

#	Article	IF	Citations
55	A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods. Journal of Clinical Pathology, 2007, 61, 119-123.	2.0	27
56	Immune Thrombocytopenia after Renal Transplantation for IgA Nephropathy. Acta Haematologica, 2007, 117, 65-67.	1.4	2
57	Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study. Pathology, 2007, 39, 580-585.	0.6	19
58	Health-related quality of life in chronic coagulation disorders. Haemophilia, 2006, 12, 633-642.	2.1	30